Résumé :
|
[BDSP. Notice produite par INIST-CNRS n988R0x9. Diffusion soumise à autorisation]. The authors further analyzed results from the Women's Health Initiative randomized trials (1993-2004) of conjugated equine estrogens, with or without medroxyprogesterone acetate, focusing on health benefits versus risks among women who initiated hormone therapy soon after menopause. Data from the Women's Health Initiative observational study (1993-2004) were included in some analyses for additional precision. Results are presented here for incident coronary heart disease, stroke, venous thromboembolism, breast cancer, colorectal cancer, endometrial cancer, or hip fracture ; death from other causes ; a summary global index ; total cancer ; and total mortality. Hazard ratios for breast cancer and total cancer were comparatively higher (P
|